Skip to main content
Top
Published in: BMC Ophthalmology 1/2024

Open Access 01-12-2024 | Edema | Research

Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema

Authors: So Hyung Lee, Geun Woo Lee, Soo Jung Lee, Seong Gyu Kim

Published in: BMC Ophthalmology | Issue 1/2024

Login to get access

Abstract

Background

This study investigated the effects of systemic factors in response to intravitreal injections in patients with macular edema due to non-proliferative diabetic retinopathy (NPDR).

Methods

We retrospectively reviewed the medical records of patients treated with intravitreal injections for macular edema secondary to NPDR between January 2018 and January 2021. The patients were divided into three groups according to the injection response. When patients with diabetic macular edema showed 20µ or more reduction in central retinal thickness compared to baseline, they were classified as responsive group, and if not, they were classified as refractory group. The responsive group was further divided into the complete and incomplete response groups. Patients with complete disappearance of edema at seven months were classified as the complete response group, whereas those in which edema did not disappear were classified as the incomplete response group. The clinical characteristics of each group, including medical history, ophthalmic examination results, and laboratory examination results at the time of diagnosis, were analyzed.

Results

Of the 112 eyes (91 patients) that satisfied the inclusion criteria, 89 (77 patients) in the responsive group and 23 (14 patients) in the refractory group were included in the analysis. The responsive group was further divided into the complete (51 eyes) and incomplete (38 eyes) response groups. The refractory group had significantly higher glycated hemoglobin levels and significantly lower estimated glomerular filtration rates than the responsive group (p = 0.026 and p = 0.012, respectively). In the multivariate logistic regression analysis, both factors were found to be significant in predicting the degree of response (all p < 0.05). No factor showed a significant difference between the incomplete and complete response groups(all p > 0.05).

Conclusions

In macular edema caused by NPDR, low glomerular filtration rates and high glycated hemoglobin levels may be used as predictors of poor response to intravitreal injection therapy. In addition to blood glucose control, education should be provided regarding the need for the continuous monitoring of renal function.
Literature
1.
go back to reference B M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.CrossRef B M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.CrossRef
2.
go back to reference Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.CrossRefPubMed Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.CrossRefPubMed
3.
go back to reference Ozer PA, Unlu N, Demir MN, Hazirolan DO, Acar MA, Duman S. Serum lipid profile in diabetic macular edema. J Diabetes Complications. 2009;23(4):244–8.CrossRefPubMed Ozer PA, Unlu N, Demir MN, Hazirolan DO, Acar MA, Duman S. Serum lipid profile in diabetic macular edema. J Diabetes Complications. 2009;23(4):244–8.CrossRefPubMed
4.
go back to reference Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of Diabetic Retinopathy: III. Prevalence and risk of Diabetic Retinopathy when Age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527–32.CrossRefPubMed Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of Diabetic Retinopathy: III. Prevalence and risk of Diabetic Retinopathy when Age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527–32.CrossRefPubMed
5.
go back to reference Hsieh YT, Tsai MJ, Tu ST, Hsieh MC. Association of Abnormal Renal Profiles and proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population with type 2 diabetes. JAMA Ophthalmol. 2018;136(1):68–74.CrossRefPubMed Hsieh YT, Tsai MJ, Tu ST, Hsieh MC. Association of Abnormal Renal Profiles and proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population with type 2 diabetes. JAMA Ophthalmol. 2018;136(1):68–74.CrossRefPubMed
6.
go back to reference Zhuang X, Cao D, Yang D, Zeng Y, Yu H, Wang J, Kuang J, Xie J, Zhang S, Zhang L. Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study. BMJ Open. 2019;9(9):e031194.CrossRefPubMedPubMedCentral Zhuang X, Cao D, Yang D, Zeng Y, Yu H, Wang J, Kuang J, Xie J, Zhang S, Zhang L. Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study. BMJ Open. 2019;9(9):e031194.CrossRefPubMedPubMedCentral
7.
go back to reference Meyer J, Fry C, Turner A, Razavi H. Intravitreal dexamethasone versus bevacizumab in Aboriginal and Torres Strait Islander patients with diabetic macular oedema: the OASIS study (a randomised control trial). Clin Exp Ophthalmol. 2022;50(5):522–33.CrossRefPubMed Meyer J, Fry C, Turner A, Razavi H. Intravitreal dexamethasone versus bevacizumab in Aboriginal and Torres Strait Islander patients with diabetic macular oedema: the OASIS study (a randomised control trial). Clin Exp Ophthalmol. 2022;50(5):522–33.CrossRefPubMed
8.
go back to reference Park HY, Yi K, Kim HK. Intraocular pressure elevation after Intravitreal Triamcinolone Acetonide Injection. Korean J Ophthalmol. 2005;19(2):122–7.CrossRefPubMed Park HY, Yi K, Kim HK. Intraocular pressure elevation after Intravitreal Triamcinolone Acetonide Injection. Korean J Ophthalmol. 2005;19(2):122–7.CrossRefPubMed
9.
go back to reference Singh IP, Ahmad SI, Yeh D, Challa P, Herndon LW, Allingham RR, Lee PP. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;138(2):286–7.CrossRefPubMed Singh IP, Ahmad SI, Yeh D, Challa P, Herndon LW, Allingham RR, Lee PP. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;138(2):286–7.CrossRefPubMed
10.
go back to reference Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1699–705.CrossRefPubMed Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1699–705.CrossRefPubMed
11.
go back to reference Ababneh OH, Yousef YA, Gharaibeh AM, Abu Ameerh MA, Abu-Yaghi NE. Al Bdour MD: Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization. RETINA. 2013;33(4):748–55.CrossRefPubMed Ababneh OH, Yousef YA, Gharaibeh AM, Abu Ameerh MA, Abu-Yaghi NE. Al Bdour MD: Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization. RETINA. 2013;33(4):748–55.CrossRefPubMed
12.
go back to reference El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol. 2007;1(2):149–55.PubMedPubMedCentral El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol. 2007;1(2):149–55.PubMedPubMedCentral
13.
go back to reference Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L. Influence of Glycosylated Hemoglobin on the efficacy of Ranibizumab for Diabetic Macular Edema: a Post Hoc Analysis of the RIDE/RISE trials. Ophthalmology. 2015;122(8):1573–9.CrossRefPubMed Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L. Influence of Glycosylated Hemoglobin on the efficacy of Ranibizumab for Diabetic Macular Edema: a Post Hoc Analysis of the RIDE/RISE trials. Ophthalmology. 2015;122(8):1573–9.CrossRefPubMed
14.
go back to reference Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, Zanella MT, Ehlers JP. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166–70.CrossRefPubMed Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, Zanella MT, Ehlers JP. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166–70.CrossRefPubMed
15.
go back to reference Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952.CrossRefPubMedPubMedCentral Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952.CrossRefPubMedPubMedCentral
16.
go back to reference Karlberg C, Falk C, Green A, Sjolie AK, Grauslund J. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2012;49(4):263–8.CrossRefPubMed Karlberg C, Falk C, Green A, Sjolie AK, Grauslund J. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2012;49(4):263–8.CrossRefPubMed
17.
go back to reference He F, Xia X, Wu XF, Yu XQ, Huang FX. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. Diabetologia. 2013;56(3):457–66.CrossRefPubMed He F, Xia X, Wu XF, Yu XQ, Huang FX. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. Diabetologia. 2013;56(3):457–66.CrossRefPubMed
18.
go back to reference Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic Retinopathy in patients with Diabetic Nephropathy: Development and Progression. PLoS ONE. 2016;11(8):e0161897.CrossRefPubMedPubMedCentral Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic Retinopathy in patients with Diabetic Nephropathy: Development and Progression. PLoS ONE. 2016;11(8):e0161897.CrossRefPubMedPubMedCentral
19.
go back to reference Kume A, Kashiwagi K. Systemic and ocular diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus. BMC Ophthalmol. 2020;20(1):309.CrossRefPubMedPubMedCentral Kume A, Kashiwagi K. Systemic and ocular diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus. BMC Ophthalmol. 2020;20(1):309.CrossRefPubMedPubMedCentral
20.
go back to reference Hwang H, Chae JB, Kim JY, Moon BG, Kim DY, Changes in optical coherence tomography findings in patients with chronic renal failure undergoing dialysis for the first time. 2019, 39(12):2360–8. Hwang H, Chae JB, Kim JY, Moon BG, Kim DY, Changes in optical coherence tomography findings in patients with chronic renal failure undergoing dialysis for the first time. 2019, 39(12):2360–8.
21.
go back to reference Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA. 3rd, Diabetic Retinopathy Clinical Research N: factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–61.CrossRefPubMedPubMedCentral Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA. 3rd, Diabetic Retinopathy Clinical Research N: factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–61.CrossRefPubMedPubMedCentral
22.
go back to reference Parravano M, Costanzo E, Borrelli E, Sacconi R, Virgili G, Sadda SR, Scarinci F, Varano M, Bandello F, Querques G. Appearance of cysts and capillary non perfusion areas in diabetic macular edema using two different OCTA devices. Sci Rep. 2020;10(1):800.CrossRefPubMedPubMedCentral Parravano M, Costanzo E, Borrelli E, Sacconi R, Virgili G, Sadda SR, Scarinci F, Varano M, Bandello F, Querques G. Appearance of cysts and capillary non perfusion areas in diabetic macular edema using two different OCTA devices. Sci Rep. 2020;10(1):800.CrossRefPubMedPubMedCentral
23.
go back to reference Mirshahi R, Riazi-Esfahani H, Khalili Pour E, Fadakar K, Yarmohamadi P, Alemzadeh SA, Chaibakhsh S, Falavarjani KG. Differentiating features of OCT angiography in diabetic macular edema. Sci Rep. 2021;11(1):23398.CrossRefPubMedPubMedCentral Mirshahi R, Riazi-Esfahani H, Khalili Pour E, Fadakar K, Yarmohamadi P, Alemzadeh SA, Chaibakhsh S, Falavarjani KG. Differentiating features of OCT angiography in diabetic macular edema. Sci Rep. 2021;11(1):23398.CrossRefPubMedPubMedCentral
24.
go back to reference Podkowinski D, Beka S, Mursch-Edlmayr AS, Strauss RW, Fischer L, Bolz M. A swept source optical coherence tomography angiography study: imaging artifacts and comparison of non-perfusion areas with fluorescein angiography in diabetic macular edema. PLoS ONE. 2021;16(4):e0249918.CrossRefPubMedPubMedCentral Podkowinski D, Beka S, Mursch-Edlmayr AS, Strauss RW, Fischer L, Bolz M. A swept source optical coherence tomography angiography study: imaging artifacts and comparison of non-perfusion areas with fluorescein angiography in diabetic macular edema. PLoS ONE. 2021;16(4):e0249918.CrossRefPubMedPubMedCentral
Metadata
Title
Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema
Authors
So Hyung Lee
Geun Woo Lee
Soo Jung Lee
Seong Gyu Kim
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2024
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-024-03432-7

Other articles of this Issue 1/2024

BMC Ophthalmology 1/2024 Go to the issue